But all of this is still very new in terms of how to manage patients effectively.For the study, researchers looked at the use of semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) among patients undergoing weight-loss surgery, analyzing nearly 365,000 patients between 2018 and 2024.The proportion of patients who received at least one GLP-1 prescription in the year leading up to their surgery exploded to more than 29% in the fourth quarter of 2024 from just under 2% in the first quarter of 2020, results show.Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of 2024 from 2% in the first quarter of 2020, researchers found.GLP-1 use among patients with type 2 diabetes was even higher, rising to 45% from 11% during the same period.The median age of the patients was 43, and they had a median preoperative body mass index (BMI) of 46
Research published in Naunyn-Schmiedeberg Archives of Pharmacology confirmed this in isolated human atrial tissue
Theres a serious lack of clear information, limited resources, and new GLP-1 products popping up almost daily
What to do instead: track waist and hip measurements every two weeks at the same point in your cycle
Heres what Tomas Weber from The New York Times noted: Though many ultra-processed foods and drinks turn off a lot of GLP-1 users, some are breaking through: On GLP-1 forums, people celebrate Fairlife, a line of sweet protein shakes owned by Coca-Cola.[23] The graveyard of diet food brands like Slim Fast and South Beach Diet should caution most executives against kicking off a narrowly conceived innovate-to-defend strategy
